3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
59
Squamous Cell Carcinoma of Head and Neck
38
Nasopharyngeal Carcinoma
27
Lung Neoplasms
26
Biliary Tract Neoplasms
24
Uterine Cervical Neoplasms
23
Esophageal Squamous Cell Carcinoma
20
Oropharyngeal Neoplasms
19
Cholangiocarcinoma
18
Head and Neck Neoplasms
17
Urinary Bladder Neoplasms
14
Ovarian Neoplasms
14
Neoplasms
14
Neoplasm Metastasis
13
Esophageal Neoplasms
13
Colorectal Neoplasms
12
Carcinoma
12
Stomach Neoplasms
10
Small Cell Lung Carcinoma
9
Carcinoma, Squamous Cell
9
Mouth Neoplasms
8
Carcinoma, Transitional Cell
8
Laryngeal Neoplasms
7
Hypopharyngeal Neoplasms
7
Recurrence
6
Pancreatic Neoplasms
6
Nasopharyngeal Neoplasms
5
Gallbladder Neoplasms
5
Endometrial Neoplasms
5
Breast Neoplasms
5
Interventions
pembrolizumab
1
Pemetrexed
1
Control Groups
1
Cisplatin
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Pathologic Processes
×
Cisplatin
×
Clear all
NCT06119581
2026-05-19
SUNRAY-01
Eli Lilly and Company
Phase 3
Recruiting
1,264 enrolled